查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929580

GalNAc递送技术市场依治疗领域、临床阶段、作用机制及最终使用者划分，全球预测，2026-2032年

GalNAc Delivery Technology Market by Therapeutic Area, Clinical Stage, Mechanism Of Action, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 Galnac 输送技术市值为 5.5237 亿美元，预计到 2026 年将成长至 5.9921 亿美元，预计到 2032 年将达到 9.1012 亿美元，复合年增长率为 7.39%。

关键市场统计数据
基准年 2025 5.5237亿美元
预计年份：2026年 5.9921亿美元
预测年份 2032 9.1012亿美元
复合年增长率 (%) 7.39%

基于 GalNAc 的肝细胞靶向 RNA 疗法的基本科学原理、转化里程碑及其对产业和医疗相关人员的战略意义

GalNAc介导的递送代表了寡核苷酸疗法在高效肝细胞靶向给药方面的一项突破。透过利用N-乙酰半乳糖胺配体与去Glico受体的高亲和性结合，研发人员在肝臟标靶治疗计画中实现了更高的药物摄取效率和治疗指数。本文阐述了RNA疗法生态系统中相关技术原理、近期转化里程碑以及对研发人员、投资者和临床相关人员的策略意义。

科学创新、监管政策的明确性以及策略合作的整合，推动了基于 GalNAc 的疗法和商业化途径的成熟生态系统。

在科学、监管和商业性因素的共同推动下，GalNAc递送技术正经历着一场变革性的转变。偶联化学和连接子设计的进步提高了有效载荷的柔软性，为支持超越传统RNA干扰的多种作用机制奠定了基础。因此，研发人员正在探索将GalNAc与新一代寡核苷酸化学相结合的联合疗法，以增强治疗效果的持久性和标靶选择性。这项科学进步正在重塑候选药物的优先排序，并开拓了先前被认为超出肝臟标靶治疗范围的适应症。

预计2025年前后关税政策发展和贸易政策措施对寡核苷酸计画供应链、筹资策略和区域製造决策的影响

2025 年前公布的贸易政策和关税正对支持寡核苷酸和偶联物生产的全球供应链施加巨大压力。影响原材料、某些类别的实验室设备和中间体化学品供应的关税正在推高到岸成本，使供应商选择更加复杂，并促使企业重新评估其库存和筹资策略。为此，研发人员和契约製造正越来越多地考虑近岸外包和供应商多元化，以此来降低跨境关税波动带来的风险。

结合治疗领域、临床开发阶段、作用机制和最终用户优先顺序的深度細項分析，为您的 GalNAc 计画揭示客製化的发展路径。

我们基于细分市场的 GalNAc 递送领域分析，结合治疗领域、临床阶段、作用机制和最终用户，揭示了其中蕴含的许多机会。按治疗领域划分，该领域涵盖心血管疾病（细分为动脉粥样硬化和血脂异常症）、肝臟疾病（细分为乙型肝炎和非酒精性脂肪性肝炎）、代谢性疾病（细分为遗传性高胆固醇症和原发性高草酸尿症）以及肿瘤学（重点关注肝细胞癌）。这些针对特定适应症的路径驱动着不同的标靶检验策略、生物标记选择和终点指标，进而影响临床试验设计和商业化计画。

区域发展、製造和商业化趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的战略选择。

区域趋势将对基于 GalNAc 的疗法的研发、生产和商业化产生重大影响，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。美洲的生态系统得益于密集的生物技术丛集、创业投资管道以及支持快速临床开发的完善法规结构。这些优势促进了早期创新和伙伴关係协议的达成，从而加速转化研究并主导全球专案。

观察到的企业策略和产能投资表明，平台整合、专注于生物技术创新和 CRO（受託研究机构）扩张，这些共同加速了 GalNAc 疗法的开发。

GalNAc递送领域主要企业的活动展现出多元化的策略态势，涵盖了从专注于平台型规模化生产的公司到针对特定适应症的专业研发公司。现有製药公司正透过收购和策略联盟整合自身能力，以获取后期研发资产和生产技术。这些措施反映出其致力于降低研发管线风险，并收购可整合到多个治疗领域的成熟递送平台。

为开发者提供的实用策略建议：整合科学差异化、供应链韧性和市场进入规划，以加速 GalNAc 专案的成功

为了充分利用 GalNAc 递送技术的机会，产业领导者应采取多维策略，整合科学差异化、供应链韧性和市场进入准备。首先，应优先投资于连接子化学和有效载荷优化，以提高靶向特异性并最大限度地减少脱靶效应。这些技术差异化将是确保临床优势和吸引合作伙伴的关键。同时，应儘早调整分析开发和品质体系，以确保製程验证能够随着临床开发进展和监管要求而扩展。

结合专家访谈、文献综合和情境分析的透明且可复製的调查方法将为 GalNAc相关人员产生可操作的见解。

本研究整合了一手和二手讯息，旨在建构对 GalNAc 递送领域的全面视角。一级资讯来源包括与药物发现、转化开发、生产製造和商业策略等领域的专家进行的结构化访谈和检验讨论。基于这些讨论，我们对平台优势、开发瓶颈以及主要参与者的竞争地位进行了定性评估。此外，调查方法还纳入了对同行评审科学文献、监管指导文件和公开资讯的系统性回顾，以确保研究结果的可验证性和检验性。

一项全面的技术、监管和商业计划，旨在将 GalNAc 的潜力转化为持续的临床和市场影响。

总之，GalNAc递送技术代表了一种稳健且日益检验的肝臟定向RNA疗法途径，其应用范围涵盖心血管、肝臟、代谢和肿瘤等多个领域。偶联化学和有效载荷相容性方面的科学进步提高了多种疗法的治疗指数，而监管政策的明确和战略伙伴关係则促进了高效的临床应用。同时，关税驱动的供应链重组和区域製造地转移等外部压力凸显了积极主动的产业计画的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. GalNAc递送技术市场（依治疗领域划分）

  • 心血管疾病
    • 动脉粥状硬化
    • 血脂异常症
  • 肝病
    • B型肝炎
    • 非酒精性脂肪性肝炎
  • 代谢性疾病
    • 遗传性高胆固醇症
    • 原发性草酸尿症
  • 肿瘤学

9. GalNAc递送技术市场（依临床阶段划分）

  • 商业的
  • 第一/二期
    • 第一阶段
    • 第二阶段
  • 第三阶段
  • 临床前

10. GalNAc递送技术市场依作用机制划分

  • 反义寡核苷酸
    • 吗啉代寡核苷酸
    • 硫代磷酸酯
  • 基因编辑
    • CRISPR-Cas9
    • 塔伦
  • mRNA疗法
    • 治疗性mRNA
    • 疫苗mRNA
  • RNA干扰
    • ShRNA
    • siRNA

11. GalNAc递送技术市场（依最终用户划分）

  • 学术机构
  • 生技公司
  • CRO（受託研究机构）
  • 製药公司

12. GalNAc递送技术市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. GalNAc递送技术市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国 GalNAc 递送技术市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国 GalNAc 递送技术市场

第十六章：中国 GalNAc 递送技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac NV
  • Editas Medicine, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A380695182F

The GalNAc Delivery Technology Market was valued at USD 552.37 million in 2025 and is projected to grow to USD 599.21 million in 2026, with a CAGR of 7.39%, reaching USD 910.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 552.37 million
Estimated Year [2026] USD 599.21 million
Forecast Year [2032] USD 910.12 million
CAGR (%) 7.39%

Foundational scientific principles, translational milestones, and strategic implications of GalNAc-enabled hepatocyte-targeted RNA therapeutics for stakeholders across industry and medicine

GalNAc-mediated delivery has become a defining advance in the efficient hepatocyte-targeted administration of oligonucleotide therapeutics. By leveraging the high-affinity binding of N-acetylgalactosamine ligands to asialoglycoprotein receptors, developers have achieved improved uptake and therapeutic index in liver-directed programs. This introduction establishes the technological principles, recent translational milestones, and the strategic implications for developers, investors, and clinical stakeholders who are positioning themselves in the RNA therapeutics ecosystem.

Across the scientific continuum, GalNAc conjugation has enabled lower dose requirements, reduced systemic exposure, and clearer pharmacodynamic relationships for a range of modalities including small interfering RNA and antisense oligonucleotides. Consequently, recent clinical entries and late-stage programs illustrate how target biology and linker chemistry interplay to define both efficacy and safety. Transitioning from bench to bedside, program teams must weigh manufacturing complexity, regulatory expectations for oligonucleotide quality attributes, and the evolving real-world evidence base that will ultimately drive adoption in diverse therapeutic areas.

This section sets the stage for deeper analysis by highlighting the platform's core strengths-target specificity, scalable conjugation chemistries, and growing clinical validation-while also signposting the persistent challenges that require strategic mitigation. Those challenges include optimizing payload stability, navigating intellectual property landscapes, and aligning commercial models with payer and provider expectations for novel gene-silencing therapies. With that context, the subsequent sections examine structural shifts in the competitive landscape, regulatory and trade influences, and actionable recommendations for industry leaders.

Converging scientific innovations, regulatory clarifications, and strategic collaborations driving a matured ecosystem for GalNAc-enabled therapeutics and commercialization pathways

The GalNAc delivery landscape is undergoing transformative shifts driven by converging scientific, regulatory, and commercial forces. Advances in conjugation chemistry and linker design have increased payload flexibility, enabling the platform to support diverse mechanisms of action beyond classical RNA interference. As a result, developers are pairing GalNAc with next-generation oligonucleotide chemistries and exploring combination approaches that amplify therapeutic durability and target selectivity. This scientific progress is reshaping candidate prioritization and opening indications previously considered out of scope for liver-directed strategies.

Concurrently, regulatory pathways are adapting to the specificities of oligonucleotide therapeutics, with agencies issuing guidance that clarifies expectations for impurity control, pharmacokinetic bridging, and post-market safety monitoring. These regulatory clarifications reduce uncertainty for sponsors but also elevate the bar for manufacturing controls and analytical validation. In parallel, industry alliances and public-private partnerships have intensified, enabling shared access to specialized manufacturing capabilities and bolstering translational throughput.

Market dynamics are shifting as larger pharmaceutical companies increasingly collaborate with or acquire biotech firms possessing proprietary GalNAc-enabled assets, accelerating commercialization timelines. At the same time, capital formation has become more outcome-driven, prioritizing programs with clear biomarkers and tolerability profiles that demonstrate durable target engagement. Taken together, these shifts are producing a more mature ecosystem in which scientific innovation, regulatory harmonization, and commercial strategy co-evolve to de-risk late-stage development and support broader clinical adoption.

How tariff dynamics and trade policy measures scheduled around 2025 are reshaping supply chains, procurement strategies, and regional manufacturing decisions for oligonucleotide programs

Trade policy and tariff measures announced in the run-up to 2025 are exerting measurable pressure on global supply chains that support oligonucleotide and conjugate manufacturing. Tariff actions affecting raw materials, certain laboratory equipment classes, and intermediate chemical inputs can increase landed costs, complicate supplier selection, and prompt firms to re-evaluate their inventory and sourcing strategies. In response, developers and contract manufacturers are increasingly assessing nearshoring and supplier diversification as mechanisms to reduce exposure to cross-border tariff volatility.

Beyond direct cost effects, tariffs can catalyze longer lead times and administrative burdens related to customs classifications and compliance documentation. These operational frictions have downstream consequences for clinical timelines when clinical supply manufacturing slots become more contested. Consequently, strategic procurement planning now routinely incorporates tariff sensitivity analyses and scenario-based supply-chain modeling to preserve program momentum.

Importantly, the cumulative impact of tariffs is not limited to cost inflation. Tariff-induced shifts in supplier geography can reshape regional clustering of capabilities, potentially accelerating capacity build-out in areas with preferential trade conditions. As a result, partnerships with contract research and manufacturing organizations are being renegotiated to include clauses that address tariff pass-through, contingency supply, and collaborative inventory management. For industry leaders, the practical implication is a need to integrate trade-policy foresight into clinical stage planning, capital allocation, and outsourcing strategies to maintain resilience against 2025-era tariff dynamics.

Deep segmentation insights that combine therapeutic focus, clinical development stage, mechanistic modality, and end user priorities to reveal tailored pathways for GalNAc program advancement

Segmentation-based analysis of the GalNAc delivery space reveals nuanced opportunity zones when therapeutic area, clinical stage, mechanism of action, and end user are considered in combination. Based on therapeutic area, the landscape spans cardiovascular diseases-subdivided into atherosclerosis and dyslipidemia-liver diseases-subdivided into hepatitis B and nonalcoholic steatohepatitis-metabolic disorders-subdivided into familial hypercholesterolemia and primary hyperoxaluria-and oncology with a focus on hepatocellular carcinoma. These indication-specific pathways drive distinct target validation strategies, biomarker selection, and endpoints that influence both clinical design and commercialization planning.

In terms of clinical stage segmentation, the market encompasses commercial assets, Phase I/II programs that further bifurcate into Phase I and Phase II trials, Phase III candidates, and preclinical research. Differences across these stages affect investor risk appetites, partner interest, and the technical requirements for manufacturing scale-up. Early-stage programs prioritize target engagement assays and delivery optimization, while later stage assets require robust process validation, long-term safety data, and market-access planning.

For mechanism of action, GalNAc-enabled platforms are being deployed across antisense oligonucleotides-further classified into morpholino and phosphorothioate chemistries-gene editing modalities such as Crispr Cas9 and Talen, mRNA therapies distinguished between therapeutic mRNA and vaccine mRNA, and RNA interference approaches including shRNA and siRNA. Each modality imposes distinct constraints on payload size, stability, and formulation, which in turn determine analytic strategies and regulatory dossiers. Finally, consideration of end users-academic institutions, biotechnology firms, contract research organizations, and pharmaceutical companies-illuminates differing priorities: academic groups tend to emphasize exploratory science and translational proof-of-concept, biotech firms focus on de-risking and partnering, CROs concentrate on operational execution, and pharmaceutical companies emphasize late-stage validation and commercialization readiness. Understanding these intersecting segmentations enables stakeholders to align capabilities and investments with the most relevant pathways to clinical and commercial success.

Regionally differentiated development, manufacturing, and commercialization dynamics shaping strategic choices across the Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics significantly influence the development, manufacturing, and commercial deployment of GalNAc-enabled therapeutics, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, ecosystem strength derives from dense biotech clusters, access to venture capital, and established regulatory frameworks that support rapid clinical advancement. These attributes favor early-stage innovation and partnership deals that accelerate translational work and global program leadership.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and targeted public funding have encouraged formation of centers of excellence in oligonucleotide chemistry and clinical trial networks. These regional collaborations can shorten recruitment timelines for specific hepatology and metabolic indications and support multicenter Phase II and Phase III studies. In addition, manufacturers in the region are investing in analytical capabilities that align with increasingly stringent quality expectations.

The Asia-Pacific region has emerged as a pivotal hub for both clinical development and manufacturing scale-up. Strong government support for biotechnology, competitive manufacturing costs, and growing domestic markets make the region an attractive locus for late-stage production and commercial launch strategies. Moreover, patient populations with high disease prevalence for certain liver and metabolic disorders create compelling opportunities for localized clinical studies. Taken together, regional strategies must balance regulatory pathways, clinical trial feasibility, intellectual property considerations, and supply-chain logistics to optimize program outcomes in each geography.

Observed corporate strategies and capability investments indicating platform consolidation, biotech innovation focus, and CRO expansion that collectively accelerate GalNAc therapeutic development

Key company behaviors in the GalNAc delivery arena reveal a spectrum of strategic postures from platform-centric scale-ups to indication-focused specialist developers. Established pharmaceutical companies are consolidating capabilities through acquisitions and strategic alliances that secure late-stage assets and manufacturing know-how. These moves reflect an emphasis on de-risking pipelines and acquiring validated delivery platforms that can be integrated across multiple therapeutic franchises.

Biotechnology firms continue to drive innovation at the chemistry and payload levels, advancing proprietary linker technologies, novel conjugation strategies, and bespoke oligonucleotide sequences. Smaller firms often pursue partnering strategies with larger organizations to access commercialization infrastructure, while simultaneously protecting high-value intellectual property through sophisticated patent portfolios and defensive filings. Contract research and manufacturing organizations are expanding capacity and quality systems to serve the specialized needs of oligonucleotide developers, investing in analytics, sterile fill-finish capabilities, and supply-chain management tools.

Academic institutions and translational centers remain critical sources of discovery-stage innovation and early clinical proof-of-concept. These organizations frequently collaborate with industry partners to move promising GalNAc-enabled therapies into human studies. Across the competitive landscape, successful companies combine deep scientific expertise with operational rigor and market-focused development plans. They also demonstrate an ability to navigate regulatory expectations proactively, align with payer evidence needs, and structure partnerships that accelerate time to key inflection points.

Actionable strategic recommendations for developers to integrate scientific differentiation, supply-chain resilience, and market-access planning to accelerate GalNAc program success

Industry leaders should adopt a multi-dimensional strategy that integrates scientific differentiation, supply-chain resilience, and market-access readiness to capitalize on GalNAc delivery opportunities. First, prioritize investments in linker chemistry and payload optimization that enhance target specificity while minimizing off-target effects; these technical differentiators will be key to securing clinical advantage and partner interest. Concurrently, align analytical development and quality systems early so that process validation scales with clinical progression and regulatory expectations.

Second, incorporate trade-policy and tariff scenario planning into procurement and outsourcing decisions. Establish contractual flexibility with suppliers and CROs to mitigate cost pass-through and to secure continuity of supply. Consider geographic diversification of manufacturing and the use of regional hubs to reduce exposure to single points of failure. Third, design clinical programs with clear biomarker-driven endpoints and adaptive elements that permit efficient de-risking; this approach attracts capital and enhances negotiating leverage with potential commercial partners.

Finally, craft commercial and market-access strategies that articulate the value proposition in terms payers and providers recognize-durable clinical benefit, reduced treatment burden, and demonstrable improvements in key health-economic metrics. Engage early with regulatory and HTA stakeholders to align evidence generation with reimbursement requirements. By executing on these recommendations, developers can convert technological promise into sustained clinical and commercial outcomes.

Transparent, reproducible research methodology combining expert interviews, literature synthesis, and scenario analysis to produce actionable insights for GalNAc stakeholders

This research synthesizes primary and secondary intelligence to construct a robust view of the GalNAc delivery landscape. Primary inputs include structured interviews and validation discussions with subject matter experts across discovery, translational development, manufacturing, and commercial strategy. These conversations informed qualitative assessments of platform strengths, development bottlenecks, and the competitive positioning of leading organizations. In addition, the methodology incorporated a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and public disclosures to ground findings in verifiable evidence.

Analytical methods involved cross-sectional comparison across therapeutic areas and clinical stages, triangulating mechanistic differences with operational requirements. Scenario analysis and sensitivity frameworks were applied to examine the potential impacts of trade-policy shifts and supply-chain disruptions. Validation steps included iterative expert debriefs and internal consistency checks to ensure conclusions were defensible and actionable. Where uncertainty remains, the report flags open questions and suggests targeted research priorities to reduce decision risk.

Overall, the research methodology emphasizes transparency in data sources, reproducibility in analytic approaches, and practical relevance for decision-makers seeking to deploy resources effectively. Supplemental appendices document interview protocols, literature inclusion criteria, and a glossary of technical terms to support interpretability for cross-functional teams.

Synthesis and forward-looking perspective emphasizing integrated technical, regulatory, and commercial planning to translate GalNAc promise into durable clinical and market impact

In conclusion, GalNAc delivery represents a robust and increasingly validated pathway to liver-directed RNA therapeutics, with implications that extend across cardiovascular, hepatic, metabolic, and oncologic indications. Scientific advances in conjugation chemistry and payload compatibility have improved the therapeutic index for a variety of modalities, while regulatory clarifications and strategic partnerships are facilitating efficient clinical translation. At the same time, external pressures such as tariff-driven supply-chain reconfiguration and regional manufacturing shifts underscore the need for proactive operational planning.

For stakeholders, the path forward requires an integrated approach that aligns technical development with regulatory, commercial, and procurement strategies. Those who invest early in differentiating chemistries, resilient supply chains, and evidence frameworks suitable for payer dialogue will be best positioned to convert clinical promise into sustainable patient impact. The landscape will continue to evolve as new modalities emerge and as policy and market forces reshape incentive structures, making continuous monitoring and adaptive planning essential for long-term success.

Taken together, the synthesis presented here equips decision-makers with the contextual understanding needed to prioritize initiatives, select partners, and structure investments that accelerate the development of safe, effective, and commercially viable GalNAc-enabled therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc Delivery Technology Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
    • 8.1.1. Atherosclerosis
    • 8.1.2. Dyslipidemia
  • 8.2. Liver Diseases
    • 8.2.1. Hepatitis B
    • 8.2.2. Non Alcoholic Steatohepatitis
  • 8.3. Metabolic Disorders
    • 8.3.1. Familial Hypercholesterolemia
    • 8.3.2. Primary Hyperoxaluria
  • 8.4. Oncology

9. GalNAc Delivery Technology Market, by Clinical Stage

  • 9.1. Commercial
  • 9.2. Phase I/II
    • 9.2.1. Phase I
    • 9.2.2. Phase II
  • 9.3. Phase III
  • 9.4. Preclinical

10. GalNAc Delivery Technology Market, by Mechanism Of Action

  • 10.1. Antisense Oligonucleotides
    • 10.1.1. Morpholino
    • 10.1.2. Phosphorothioate
  • 10.2. Gene Editing
    • 10.2.1. Crispr Cas9
    • 10.2.2. Talen
  • 10.3. Mrna Therapies
    • 10.3.1. Therapeutic Mrna
    • 10.3.2. Vaccine Mrna
  • 10.4. Rna Interference
    • 10.4.1. ShRNA
    • 10.4.2. SiRNA

11. GalNAc Delivery Technology Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Biotechnology Firms
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. GalNAc Delivery Technology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. GalNAc Delivery Technology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. GalNAc Delivery Technology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States GalNAc Delivery Technology Market

16. China GalNAc Delivery Technology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akcea Therapeutics, Inc.
  • 17.6. Alnylam Pharmaceuticals, Inc.
  • 17.7. Arcturus Therapeutics Holdings Inc.
  • 17.8. Arrowhead Pharmaceuticals, Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Beam Therapeutics Inc.
  • 17.12. BioNTech SE
  • 17.13. CRISPR Therapeutics AG
  • 17.14. CureVac N.V.
  • 17.15. Editas Medicine, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Ionis Pharmaceuticals, Inc.
  • 17.18. Moderna, Inc.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Pfizer Inc.
  • 17.22. Regeneron Pharmaceuticals, Inc.
  • 17.23. Roche Holding AG
  • 17.24. Sanofi S.A.
  • 17.25. Sarepta Therapeutics, Inc.
  • 17.26. Takeda Development Center Americas, Inc.
  • 17.27. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 236. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 239. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 270. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 275. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 276. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 278. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 283. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 288. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 289. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 290. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 291. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 293. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES GAL